Navigation Links
Blue Belt Technologies maakt vorming van Wetenschappelijke Heup Adviesraad bekend voor ontwikkeling van volgende NavioPFS-toepassing voor femoroacetabulair impingement
Date:4/30/2013

teit van Oxford in Engeland en combineert een klinische praktijk in sportgeneeskunde met fundamenteel wetenschappelijk onderzoek in de schade en het herstel van musculoskeletale weefsels. Dr. Coleman is ook een Associate Professor van Orthopedische Chirurgie aan het Weill Medical College van Cornell University en is hoofdteamarts van de New York Mets.

Professor Murray is professor Orthopedische Chirurgie aan de Universiteit van Oxford en een consultant orthopedisch chirurg in het Nuffield Orthopaedic Centre, Oxford. Hij is gespecialiseerd in heup- en knieoperaties en heeft op dit gebied een internationale reputatie voor klinisch onderzoek en ontwikkeling; zijn teams ondernemen biomechanische en klinische studies met betrekking tot de heup en knie.

"Ik sta te popelen om te beginnen met werken met het Blue Belt-team bij de ontwikkeling van een faciliterende robotoplossing voor FAI-operaties. We hebben reeds een goede start, aangezien de Blue Belt-technologie alle andere oplossingen ver vooruit is," aldus dr. Buly. "Ik ben van mening dat Navio-technologie voor FAI het gebruik van een arthroscopische benadering voor de behandeling van FAI zal versnellen. De flexibiliteit van een handheld robotoplossing is wat deze mogelijkheid zo geweldig maakt; het stelt me ​​in staat om geavanceerde robottechnologie te gebruiken via mijn normale arthroscopische benadering voor gecontroleerde botresectie."

"Daar we al gedurende enige tijd nauw hebben samengewerkt met deze chirurgen van wereldklasse, zijn we verheugd om de oprichting van deze Raad voor onze FAI-toepassing formeel bekend te maken," verklaarde Eric B. Timko , President en CEO van Blue Belt Technologies. "Ons team bij Blue Belt kijkt ernaar uit om nauw samen te werken met dr. Buly, dr. Murray en dr. Coleman bij het gebruik maken van onze eigen robottechnologie voor FAI, een van de snelst groeiende ingrepen in orthopedische chirur
'/>"/>

SOURCE Blue Belt Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Blue Belt Technologies Announces Formation of Hip Scientific Advisory Board for Development of Next NavioPFS Application for Femoroacetabular Impingement
2. Life Technologies Supports Global Effort to Help Accelerate Emergency Screening of Avian Influenza (H7N9) Virus
3. Update to Shareholders on Dividend Payment: Medisafe 1 Technologies Corporation Files Corporate Action Form with FINRA for the Dividend Distribution to its Shareholders
4. Flexpoint Announces Universal Settlement Involving the Medical Bed and Related Technologies
5. Nipro Diagnostics Leverages Managed IT Services from JDL Technologies to Support Growth and Technological Innovation
6. Cancer Experts Detail Advanced Radiosurgery Treatments for Lung Cancer Using Varian Medical Systems Technologies
7. Bioinformatics Market: Technologies, Patenting Trends & 2017 Forecasts
8. Flexpoint Announces Progress on the Medical Bed and Related Technologies
9. Life Technologies Partners with Ridom and Releases SeqSphere+ Software to Speed and Simplify Bacterial Typing
10. Varian Medical Systems Spotlights Industry-Leading Motion Management and Radiosurgery Technologies at ESTRO 2013 in Geneva
11. SafeCode Drug Technologies to Hire Project Manager to Market FDA Approved Painless Injection Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SAN DIEGO , Dec. 24, 2014 /PRNewswire/ ... the West, developing the proprietary Natural Killer (NK) ... announces that Dr. Patrick Soon-Shiong , NantWorks ... into a definitive agreement to purchase approximately $48 ... In connection with the investment, he will be ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 1, 2011 Novartis Pharmaceuticals Corporation ("Novartis") will showcase ... and investigational agents at the 47th Annual Meeting of ... underscore the company,s commitment to developing treatments to improve ... our commitment to R&D and collaborations with the scientific ...
... (Nasdaq: NBIX ) announced today that Kevin Gorman, ... presenting at the Jefferies 2011 Global Healthcare Conference in New ... on Tuesday, June 7, 2011 at 11:00 a.m. Eastern Time ... and may be accessed on the Company,s website at ...
Cached Medicine Technology:Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 3Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 4Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 5Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 6Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 7Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 8Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 9Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 10Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 11Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 12Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 13Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 14Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 15Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 16Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 17Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 18
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
(Date:12/25/2014)... updated its blog to provide professional shopping tips on wedding and ... LunaDress.co.uk come with big discounts, up to 80 percent off. , ... to be a most exciting memory and can show off a ... a wedding. On the updated fashion blog, ladies can now find ... day . , Going out with friends to a party is ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... presented today at the annual meeting of the Radiological ... evidence of the benefit of annual screening ultrasound for ... for breast cancer. In addition, the study confirmed that ... "We found that annual screening with ultrasound in ...
... ... transplant center and the first for Chicago’s south and southwest suburbs, following formal approval ... Review Board. , ... Springfield, Ill. (Vocus) -- Advocate Christ Medical Center in Oak Lawn, Ill. ...
... ... announces that a new market research report ... The Future of Central Nervous System Diseases ... Benchmarking, Product Pipeline and Deals Analysis ...
... , NEW YORK, ... market research report is available in its catalogue: ... Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline ... , Summary , The author ...
... The Kerlan Jobe Orthopaedic Clinic, a sports medicine clinic in ... million to settle allegations that it received illegal kickbacks from ... , The settlement resolves allegations that HealthSouth paid ... grants, donations to the Kerlan Jobe Foundation, loan forgiveness on ...
... Ky., Dec. 1 A scientist who broadened the understanding ... control and relieve it -- has won the 2010 University ... professor emeritus at McGill University in Montreal, was selected for ... not at the point of injury but instead in their ...
Cached Medicine News:Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12